Directorate Change
March 19 2010 - 3:00AM
UK Regulatory
TIDMMDST
RNS Number : 8324I
Medicsight Plc
19 March 2010
+------------------------------+------------------------------+
| Press Release | 19 March 2010 |
+------------------------------+------------------------------+
Medicsight Plc
("Medicsight" or "the Company")
Board Appointment
Troy Robinson appointed to Medicsight Board
Medicsight Plc (AIM: MDST), industry leader in the development of Computer-Aided
Detection (CAD) and image analysis software which assists in the early detection
and diagnosis of disease, is pleased to announce that Mr Troy Robinson (aged 34)
has been appointed to the Board as Chief Financial Officer (CFO) and Company
Secretary with immediate effect.
Troy joined Medicsight in February 2007 as Group Financial Controller after a
successful career with IVAX pharmaceuticals and HP foods. During his tenure with
Medicsight, Troy has played a pivotal role in both the Medicsight IPO and the
subsequent global expansion of the finance function. Troy was appointed CFO in
February 2009, as a non Board position, and has continued to contribute to The
Company's success. Troy is an associate of the Chartered Institute of
Management Accountants and holds a Bachelor of Arts degree from Manchester
Metropolitan University.
Allan Rowley, CEO of Medicsight, commented "I am delighted to appoint Troy to
the Board of Medicsight. He has made a significant contribution since joining
the Company and I look forward to continuing to work with him as a member of the
Medicsight Board."
This announcement sets out the disclosures required pursuant to Schedule 2,
paragraph (g) of the AIM Rules for Companies in respect of this appointment.
Troy Robinson holds interests in 300,000 Medicsight Plc Scheme J Share Options
awarded on 15 May 2009. Scheme J will vest in equal one-sixths every six months
for three years following the grant date.
Troy Robinson was a director of 115 Murray Road Management Company Limited
between 2004 and 2005.
- ENDS -
For further information:
+------------------------------------+------------------------+
| Medicsight PLC | www.medicsight.com |
+------------------------------------+------------------------+
| Allan Rowley | +44 (0)20 7605 7950 |
| | |
+------------------------------------+------------------------+
| Daniel Stewart & Company PLC | |
+------------------------------------+------------------------+
| Simon Leathers / Emma Earl | +44 (0) 20 7776 6550 |
+------------------------------------+------------------------+
Media enquiries:
+------------------------------------+------------------------+
| Abchurch | +44 (0) 20 7398 7700 |
+------------------------------------+------------------------+
| Heather Salmond / Simone Elviss / | +44 (0) 20 7398 7728 |
| Quincy Allan | |
+------------------------------------+------------------------+
| simone.elviss@abchurch-group.com | www.abchurch-group.com |
+------------------------------------+------------------------+
Notes to editors
Medicsight PLC is a UK-headquartered, research driven, leading developer of
computer-aided detection (CAD) and image analysis software for the medical
imaging market. The CAD software automatically highlights suspicious areas on
computerised tomography (CT) scans of the colon and lung, helping radiologists
to identify, measure and analyse potential disease and early indicators of
disease. Medicsight's CAD software has been developed using one of the world's
largest and most population diverse databases of verified patient CT scan data.
Medicsight's ColonCAD(TM) and LungCAD(TM) software products are seamlessly
integrated with the advanced 3D visualisation workstations of several
industry-leading imaging equipment partners.
About Computer-Aided Detection
With increasingly sophisticated radiological imaging hardware such as
Multi-Detector CT scanners, radiologists are facing a growing challenge in the
amount of detailed patient image data that they must review for each patient
examination. Some CT scan examinations generate as many as 1000 images per
patient. Review of this data by the radiologist is not only time-consuming but
also prone to error due to reader fatigue. CAD software can help the reviewing
radiologist by analysing the image data and automatically highlighting
suspicious regions of interest for closer inspection. Without CAD software some
potential abnormalities or areas of disease may be overlooked. This is critical
for diagnosis and the management of patient outcomes as early detection of
disease greatly increases the probability of successful treatment and a positive
therapeutic outcome.
About Medicsight's CAD software
Medicsight's ColonCAD(TM) and LungCAD(TM) software use an advanced CAD algorithm
to analyse CT scans of the colon and lung and automatically highlight suspicious
areas that may be indicators of disease. CAD may highlight areas easily
overlooked by the reviewing radiologist, such as small lesions or regions that
are hidden from view behind folds in the colon or normal structures and
surrounding tissue in the lung.
Both CAD products seamlessly integrate with the advanced 3D visualisation
platforms of industry-leading imaging equipment partners. The integrated systems
provide sophisticated image viewing capabilities, including 3D reconstructed
image data, with the added advantage of demonstrating automatic CAD findings to
assist clinical end users in the detection and analysis of disease. This allows
clinical end users to perform either a 'second read', where CAD findings are
displayed to the user after completion of an initial review of the CT scan data,
or a 'concurrent read' where CAD findings are displayed during the user's
initial review of the original CT scan images.
Since inception, Medicsight has developed close and lasting relationships with
some of the world's foremost clinicians in product related areas. This provides
the Company with a wealth of clinical expertise and dedicated clinical research
to support ongoing product development. Medicsight also collaborates with a
number of leading academic institutions and clinical research programmes
worldwide to develop the Company's comprehensive database of population diverse
verified patient CT scan data, thus allowing Medicsight's products to be
validated to the highest possible standards.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAKKFDQOBKDPND
Medicsight (LSE:MDST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medicsight (LSE:MDST)
Historical Stock Chart
From Jul 2023 to Jul 2024
